Infection and lung research is the focus of our two-day Fraunhofer seminar Models of Lung Disease at the CRC Hannover on June 23 to 24, 2022. The satellite workshop Alternatives to Animal Testing on the previous day can be booked separately or in combination.
more info© AdobeStock
Fraunhofer on the way to predictive models of the future – the lecture series of the CIMD competence platform features monthly talks.
more info© Fraunhofer ITEM, Ralf Mohr
Researchers of the Hannover Medical School and of Fraunhofer ITEM want to test the efficacy of an inhaled vaccine.
more info© Fraunhofer ITEM, Felix Schmitt
Institute director Prof. Thomas Thum has developed an RNA therapy for treating heart failure that has already been successfully tested in patients as part of a phase 1b clinical trial. Other RNA therapies are currently being developed to treat pulmonary fibrosis and other forms of organ fibrosis.
more info© Fraunhofer ITEM, Ralf Mohr
Alternative to animal models – advances in medicine through human-relevant disease models.
more info
With our decades of experience in infection and airway research, drug development, biomedical engineering, and in the field of chemical risk assessment, we are meanwhile involved in numerous projects to fight the COVID-19 pandemic.
more info© Fraunhofer
The High-Performance Center Medical and Pharmaceutical Engineering, launched in March, creates a platform for research and the transfer of innovations into patient care.
more info© Fraunhofer IMTE, Dr. Thomas Friedrich
The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 75 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on cardiopulmonary research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.
With a staff of 394 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.
Fraunhofer Institute for Toxicology and Experimental Medicine